Relationship between didanosine exposure and surrogate marker response in human immunodeficiency virus-infected outpatients

Antimicrobial Agents and Chemotherapy

Volumn 42, Issue 4, 1998, Pages 821-826

  Adams, John M ^a,b   Shelton, Mark J ^a,b   Hewitt, Ross G ^a,b   Grasela, Thaddeus H ^c   Deremer, Mary ^a   Morse, Gene D ^a,b,d  

^a UNIVERSITY AT BUFFALO   (United States)

^b ERIE COUNTY MEDICAL CENTER   (United States)

^c Pharmaceutical Outcomes Res Inc   (United States)

^d UNIVERSITY AT BUFFALO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIDANOSINE;

ARTICLE; CHEMOTHERAPY; DISEASE MARKER; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EXPOSURE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; OUTPATIENT; PRIORITY JOURNAL;

EID: 0031967680     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.42.4.821     Document Type: Article

References (34)

1. Ahluwalia, C., M. A. Johnson, A. Fridland, D. A. Cooney, S. Broder, and D. G. Johns. 1988. Cellular pharmacology of the anti-HIV agent 2′,3′-dideoxyadenosine, abstr. 1388, p. 349. In Proceedings of the 29th Meeting of the American Association for Cancer Research.
2. Allan, J. D., K. J. Connolly, H. Fitch, L. Jackson-Pope, C. McLaren, R. Canetta, and J. E. Groopman. 1993. Long-term follow-up of didanosine administered orally twice daily to patients with advanced human immunodeficiency virus infection and hematologic intolerance of zidovudine. Clin. Infect. Dis. 16(Suppl. 1):46-51.
3. Back, D. J., S. Ormesher, J. F. Tjia, and R. Macleod. 1992. Metabolism of 2′,3′-dideoxyinosine (ddI) in human blood. Br. J. Clin. Pharmacol. 33:319-322.
4. Barry, M., D. Back, S. Ormesher, N. Beeching, and F. Nye. 1993. Metabolism of didanosine (ddI) by erythrocytes: pharmacokinetic implications. Br. J. Clin. Pharmacol. 36:87-88.
5. Barry, M., J. L. Howe, S. Ormesher, D. J. Back, A. M. Breckenridge, C. Bergin, F. Mulcahy, N. Beeching, and F. Nye. 1994. Pharmacokinetics of zidovudine and dideoxyinosine alone and in combination in patients with the acquired immunodeficiency syndrome. Br. J. Clin. Pharmacol. 37:421-426.
6. Beal, S. L., and L. B. Sheiner. 1980. The NONMEM system. Am. Stat. 34: 118.
7. Beltangady, M., C. A. Knupp, N. Gustafson, R. H. Barbhaiya, R. Dolin, M. Seidlin, T. P. Cooley, and M. Rozencweig. 1993. Relation between plasma concentrations of didanosine and markers of antiviral efficacy in adults with AIDS or AIDS-related complex. Clin. Infect. Dis. 16(Suppl. 1):26-31.
8. Chmiel, J. S., R. Detels, R. A. Kaslow, M. VanRaden, L. A. Kingsley, and R. Brookmeyer. 1987. Factors associated with prevalent human immunodeficiency virus (HIV) infection in the multicenter AIDS cohort study. Am. J. Epidemiol. 126:568-577.
9. Collier, A. C., R. W. Coombs, M. A. Fischl, P. R. Skolnik, D. Northfelt, P. Boutin, C. J. Hooper, L. D. Kaplan, P. A. Volberding, L. G. Davis, D. R. Henrard, S. Weller, and L. Corey. 1993. Combination therapy with zidovudine and didanosine compared with zidovudine alone in HIV-1 infection. Ann. Intern. Med. 119:786-793.
10. DeRemer, M., R. D'Ambrosio, and G. Morse. 1996. Didanosine measurement by radioimmunoassay. Antimicrob. Agents Chemother. 40:1331-1334.
11. Drusano, G. L., G. J. Yuen, J. S. Lambert, M. Seidlin, R. Dolin, and F. T. Valentine. 1992. Relationship between dideoxyinosine exposure, CD4 counts, and p24 antigen levels in human immunodeficiency virus infection. Ann. Intern. Med. 116:562-566.
12. Eron, J. J., Y. K. Chow, A. M. Caliendo, J. Videler, K. M. Devore, T. P. Cooley, H. A. Liebman, J. C. Kaplan, M. S. Hirsch, and R. T. D'Aquila. 1993. Pol mutations conferring zidovudine and didanosine resistance with different effects in vitro yield multiply resistant human immunodeficiency virus type 1 isolates in vivo. Antimicrob. Agents Chemother. 37:1480-1487.
13. Fahey, J. L., J. M. G. Taylor, R. Detels, B. Hofmann, R. Melmed, P. Nishanian, and J. V. Giorgi. 1990. The prognostic value of cellular and serologic markers in infection with human immunodeficiency virus type 1. N. Engl. J. Med. 322:166-172.
14. Hartman, N. R., R. Yarchoan, J. M. Pluda, R. V. Thomas, K. S. Marczyk, S. Broder, and D. G. Johns. 1990. Pharmacokinetics of 2′,3′-dideoxyadenosine and 2′,3′-dideoxyinosine in patients with severe human immunodeficiency virus infection. Clin. Pharmacol. Ther. 47:647-654.
15. Hartman, N. R., R. Yarchoan, J. M. Pluda, R. V. Thomas, K. M. Wyvill, K. P. Flora, S. Broder, and D. G. Johns. 1991. Pharmacokinetics of 2′,3′-dideoxyinosine in patients with severe human immunodeficiency infection. II. The effects of different oral formulations and the presence of other medications. Clin. Pharmacol. Ther. 50:278-285.
16. Kahn, J. O., S. W. Lagakos, D. D. Richman, A. Cross, C. Pettinelli, S.-H. Liou, M. Brown, P. A Volberding, C. S. Crumpacker, G. Beall, H. S. Sacks, T. C. Merigan, M. Beltangady, L. Smaldone, R. Dolin, and the NIAID AIDS Clinical Trials Group. 1992. A controlled trial comparing continued zidovudine with didanosine in human immunodeficiency virus infection. N. Engl. J. Med. 327:581-587.
17. Knupp, C. A., W. C. Shyu, R. Dolin, F. T. Valentine, C. McLaren, R. R. Martin, K. A. Pittman, and R. H. Barbhaiya. 1991. Pharmacokinetics of didanosine in patients with acquired immunodeficiency syndrome or acquired immunodeficiency syndrome-related complex. Clin. Pharmacol. Ther. 49:523-535.
18. Knupp, C. A., F. M. Graziano, R. M. Dixon, and R. H. Barbhaiya. 1992. Pharmacokinetic-interaction study of didanosine and ranitidine in patients seropositive for human immunodeficiency virus. Antimicrob. Agents Chemother. 36:2075-2079.
19. Knupp, C. A., D. C. Brater, J. Relue, and R. H. Barbhaiya. 1993. Pharmacokinetics of didanosine and ketoconazole after coadministration to patients seropositive for the human immunodeficiency virus. J. Clin. Pharmacol. 33: 912-917.
20. Knupp, C. A., W. C. Shyu, E. A. Morgenthien, J. S. Lee, and R. H. Barbhaiya. 1993. Biopharmaceutics of didanosine in humans and in a model for acidlabile drugs, the pentagastrin-pretreated dog. Pharm. Res. 10:1157-1164.
21. Kozal, M. J., K. Kroodsma, M. A. Winters, R. W. Shafer, B. Efron, D. A. Katzenstein, and T. C. Merigan. 1994. Didanosine resistance in HIV-infected patients switched from zidovudine to didanosine monotherapy. Ann. Intern. Med. 121:263-268.
22. Lagakos, S. W. 1993. Surrogate markers in AIDS clinical trials: conceptual basis, validation, and uncertainties. Clin. Infect. Dis. 16(Suppl. 1):S22-S25.
23. Morse, G. D., M. J. Shelton, M. Ho, L. Bartos, M. DeRemer, and M. Ragni. 1995. Pharmacokinetics of zidovudine and didanosine during combination therapy. Antivir. Res. 27:419-424.
24. Pai, S. M., U. A. Shukla, T. H. Grasela, C. A. Knupp, R. Dolin, F. T. Valentine, C. McLaren, H. A. Liebman, R. R. Martin, K. A Pittman, and R. H. Barbhaiya. 1992. Population pharmacokinetic analysis of didanosine (2′,3′-dideoxyinosine) plasma concentrations obtained in phase I clinical trials in patients with AIDS or AIDS-related complex. J. Clin. Pharmacol. 32:242-247.
25. Prentice, R. L. 1989. Surrogate endpoints in clinical trials: definition and operational criteria. Stat. Med. 8:431-440.
26. Richardson, D., S.-H. Liou, and J. O. Kahn. 1993. Uric acid and didanosine compliance in AIDS clinical trials: an analysis of AIDS Clinical Trials Group protocols 116A and 116B/117. J. Acquired Immune Defic. Syndr. 6:1212-1223.
27. Rocci, M. L., Jr., and W. J. Jusko. 1983. LAGRAN program for area and moments in pharmacokinetic analysis. Comput. Programs Biomed. 16:203-216.
28. Rozencweig, M., C. McLaren, M. Beltangady, J. Ritter, R. Canetta, L. Schacter, S. Kelley, C. Nicaise, L. Smaldone, L. Dunkle, R. Barbhaiya, C. Knupp, A. Cross, M. Tsianco, and R. R. Martin. 1990. Overview of phase I trials of 2′,3′-dideoxyinosine (ddI) conducted on adult patients. Rev. Infect. Dis. 12(Suppl. 5):570-574.
29. Sanathanan, L. P., and C. C. Peck. 1992. Pharmacodynamic measures based on CD4 lymphocyte counts for assessing the effect of anti-HIV therapy, p. 207-222. In M. Rowland and L. Aarons (ed.), New strategies in drug development and clinical evaluation: the population approach; symposium proceedings. Commission of European Communities, Luxembourg.
30. Sheiner, L. B., and S. L. Beal. 1982. Bayesian individualization of pharmacokinetics: simple implementation and comparison with non-Bayesian methods. J. Pharm. Sci. 71:1344-1348.
31. 30a. Sheiner, L. B., and S. L. Beal. 1992. In Intermediate workshop in population pharmacokinetic data analysts using the NONMEM system.
32. Shyu, W. C., C. A. Knupp, K. A. Pittman, L. Dunkle, and R. H. Barbhaiya. 1991. Food-induced reduction in bioavailability of didanosine. Clin. Pharmacol. Ther. 50:503-507.
33. St. Clair, M. H., J. L. Martin, G. Tudor-Williams, M. C. Bach, C. L. Vavro, D. M. King, P. Kellam, S. D. Kemp, and B. A. Larder. 1991. Resistance to ddl and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase. Science 253:1557-1559.
34. Volberding, P. A., S. W. Lagakos, M. A. Koch, C. Pettinelli, M. W. Myers, D. K. Booth, H. H. Balfour, R. C. Reichman, J. A. Bartlett, M. S. Hirsch, R. L. Murphy, W. D. Hardy, R. Soeiro, M. A. Fischl, J. G. Bartlett, T. C. Merigan, N. E. Hyslop, D. D. Richman, F. T. Valentine, L. Corey, and the AIDS Clinical Trials Group of the NIAID. 1990. Zidovudine in asymptomatic human immunodeficiency virus infection: a controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. N. Engl. J. Med. 322:941-944.